Exploration and Establishment of an Early Warning System for Futile Reperfusion - A I S

Launched by XIJING HOSPITAL · Jun 23, 2025

Keywords

ClinConnect Summary

This is a prospective, observational registry study in Xi’an, China, looking to help doctors predict when trying to reopen a blocked brain artery after an acute ischemic stroke might not help a patient (futile reperfusion). Researchers will analyze a wide range of biological data collected from participants to identify signals that predict poor outcomes, with the goal of creating early warning tools and new tests to guide treatment decisions. The main outcomes they’ll track are how well a patient can function 3 months after joining the study (measured by a standard disability score) and whether any cause of death occurs within those 3 months.

Adults 18 years and older who have an acute ischemic stroke and are considered candidates for thrombectomy (clot-removal procedure) can join if they can provide informed consent. The study is being conducted at Xijing Hospital in Xi’an and is currently enrolling by invitation. Participants will be observed and data will be collected for up to 3 months, with no drugs or devices being tested. Eligible people should not have a very severe pre-stroke disability or other major brain diseases that would limit life expectancy, and they must be able to participate and follow the study procedures. An independent data monitoring committee provides oversight.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged ≥18 years 2. Acute ischemic stroke confirmed by clinical and neuroimaging criteria (CT or MRI) 3. Clinical indication for thrombectomy 4. Provision of signed informed consent
• Exclusion Criteria:
• • 1. Preexisting dementia or severe disability (modified Rankin Scale score ≥3) 2. Cerebral vascular malformations, neoplasms, abscesses, or other significant non-ischemic brain pathologies 3. Life-limiting systemic comorbidities (e.g., end-stage organ failure, metastatic malignancies) with anticipated survival \<6 months 4. Patient or legally authorized representative declined consent 5. Anticipated poor protocol adherence or loss to follow-up